Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors ; day:27 ; month:11 ; year:2023 ; pages:1-13
Cancer chemotherapy and pharmacology ; (27.11.2023), 1-13
- Creator
-
Mittra, Arjun
Coyne, Geraldine H. O’ Sullivan
Zlott, Jennifer
Kummar, Shivaani
Meehan, Robert
Rubinstein, Lawrence
Juwara, Lamin
Wilsker, Deborah
Ji, Jiuping
Miller, Brandon
Navas, Tony
Ferry-Galow, Katherine V.
Voth, Andrea Regier
Chang, Ting-Chia
Jiwani, Shahanawaz
Parchment, Ralph E.
Doroshow, James H.
Chen, Alice P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-023-04600-0
- URN
-
urn:nbn:de:101:1-2024021413130143443442
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mittra, Arjun
- Coyne, Geraldine H. O’ Sullivan
- Zlott, Jennifer
- Kummar, Shivaani
- Meehan, Robert
- Rubinstein, Lawrence
- Juwara, Lamin
- Wilsker, Deborah
- Ji, Jiuping
- Miller, Brandon
- Navas, Tony
- Ferry-Galow, Katherine V.
- Voth, Andrea Regier
- Chang, Ting-Chia
- Jiwani, Shahanawaz
- Parchment, Ralph E.
- Doroshow, James H.
- Chen, Alice P.
- SpringerLink (Online service)
Other Objects (12)
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy
Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy
Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Fortgeschrittenes Mammakarzinom: Therapie mit PARP-Inhibitoren und Relevanz der BRCA-Diagnostik
Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy
Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells